Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 with concurrent chemoradiation versus placebo with concurrent chemoradiation followed by durvalumab in unresectable stage III non-small cell lung cancer
2018-003265-34Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing cCRT plus bintrafusp alfa followed by bintrafusp alfa with cCRT plus placebo followed by durvalumab (2 arms). Primary endpoint: Progression-free survival. Started Apr 2019; status: completed.
02
Drugs
bintrafusp alfadurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003265-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003265-34.